The Growing SERD Market: Key Drivers and Future Projections Through 2036 #None #AstraZeneca #ETCAMAH #SERD
@newsen.bsky.social
@newsen.bsky.socialThe Growing SERD Market: Key Drivers and Future Projections Through 2036 #None #AstraZeneca #ETCAMAH #SERD
@wordquad.bsky.social#AstraZeneca 's cancer pipeline posts two wins and a loss
#ENHERTU and #TAGRISSO Show Promise Despite #Etcamah Setbacks
@wordquad.bsky.social#AstraZeneca ’s newly approved pill fails frontline breast cancer study
#Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from #Roche earlier this year.
@pharmaphorum.bsky.socialJust a week after getting FDA approval as a frontline treatment for HR-positive, HER2-negative #breastcancer, #AstraZeneca's #Etcamah has missed the mark in a trial designed to expand its label.
@medchemexpress.bsky.social🎯#FDA approves #camizestrant (#Etcamah, AstraZeneca) + a CDK4/6 inhibitor for #ESR1-mutated HR+/HER2− advanced or metastatic breast cancer, using ctDNA to detect emerging resistance and guide a targeted treatment switch.
#FDAApproval #BreastCancer #ctDNA #PrecisionMedicine #Oncology
@pharmaphorum.bsky.socialThe #FDA has gone against the advice of its own expert advisors and approved #AstraZeneca's #Etcamah as a frontline treatment for #breastcancer.
